Upstream Bio files for IPO in sign of life for biotech public offerings
Just hours after the US Federal Reserve announced the first interest rate cut in four years, respiratory biotech Upstream Bio revealed plans for a public listing. The Boston-area biotech unveiled its...
View ArticleTang Capital’s Concentra bids for Singular Genomics days after Deerfield offer
A second buyer has made an offer to buy the DNA sequencing company Singular Genomics Systems, potentially complicating an offer made last week by the investor Deerfield Management. On Wednesday, Tang...
View ArticleStem cell startup spun out of George Church’s lab raises $75M
GC Therapeutics, a biotech startup that is writing the recipe book for turning a stem cell into nearly any natural human cell, formally launched Thursday with $75 million in financing. The startup is...
View ArticleFDA rejects Vanda’s treatment for digestion condition, company rebukes...
The FDA flashed a red light on Vanda Pharmaceuticals’ experimental treatment for a gastrointestinal condition that disrupts the digestion process. The agency rejected tradipitant in gastroparesis on...
View ArticleClik here to view.
Sheryl Sandberg-backed Cercle raises $6M seed round with future plans to sell...
A startup that uses AI to provide insights from unstructured health data just raised a seed round, with plans to start selling its services to pharmaceutical companies in the future. Cercle uses AI to...
View ArticleClik here to view.
Exclusive: Flagship-backed Valo Health loses interim CEO ahead of key Phase 2...
Valo Health, the well-funded computational drug discovery and development startup launched by Flagship Pioneering, lost its interim CEO less than a year after he took the role, Endpoints News has...
View Article4DMT's gene therapy reduced need for standard-of-care injections to treat...
4D Molecular Therapeutics’ one-time gene therapy reduced the need for annual injections in patients with age-related blindness in a mid-stage trial. The company on Wednesday reported updated Phase 1/2...
View ArticleAscendis aims to raise $300M; Basilea inks up to $268M deal with BARDA
Plus, news about GSK, Novo Nordisk, Tanai Therapeutics, Nomic Bio, Brenus Pharma, Xspray, Achilles Therapeutics, BioXcel Therapeutics and Nuvalent: Ascendis’ $300M offering: The Danish company...
View ArticleEdgewise’s stock surges as heart drug passes early safety test
Edgewise Therapeutics has unveiled early safety data for its rare heart disease drug, with results suggesting it could do away with a black box warning seen with Bristol Myers Squibb’s Camzyos in...
View ArticleClik here to view.
Fertility benefits giant Progyny loses client that accounted for 13% of its...
Progyny lost a big client that made up around 670,000 members, the fertility benefits company said in a securities filing Wednesday, though analysts remain optimistic about the space. The unnamed...
View ArticleBioCentriq names ex-Resilient exec as new CEO; Sanofi, AstraZeneca boost...
Welcome to Endpoints News’ manufacturing briefs, where we bring you essential news on new builds, collaborations, recalls and more. Cell therapy CDMO BioCentriq has appointed Syed Husain as its new...
View ArticleFDA inspectors discover trucks carrying torn-up records leaving Indian...
Generic drug maker Granules India has been criticized by the FDA after inspectors found three trucks full of torn-up manufacturing documents and bird droppings at one of its factories. On the first...
View ArticleClik here to view.
Lasker Award goes to three scientists who pioneered research behind GLP-1 drugs
Three scientists whose work paved the way to the multibillion-dollar obesity drug boom have won the Lasker Award for “the discovery and development of GLP-1-based drugs that have revolutionized the...
View ArticleHouse committee advances PRV reauthorization, but timing on final passage...
The House Energy & Commerce Committee unanimously advanced a bill late Wednesday that would reauthorize the rare pediatric priority review voucher (PRV) program through 2029. But the House bill and...
View ArticleAligos’ trial for oral MASH treatment succeeds, but placebo group shows odd...
Aligos Therapeutics’ oral treatment for an advanced form of fatty liver disease reported positive results in a Phase 2 trial, showing it was effective at reducing fat across three dose levels. Despite...
View ArticleClik here to view.
Sanofi's BTK inhibitor again slows MS progression, but liver enzymes continue...
Sanofi released new Phase 3 data for its BTK inhibitor tolebrutinib in non-relapsing secondary progressive multiple sclerosis (nrSPMS), showing a 31% improvement in delaying onset of disease...
View ArticleGilead's Kite uncouples from Fosun in China as Yescarta faces coverage obstacles
Gilead’s Kite Pharma is separating from its cell therapy joint venture with Fosun Pharma in China, handing Fosun the reins for its CAR-T therapy Yescarta in the region. Other foreign drugmakers have...
View ArticleClik here to view.
Lexicon's president to step down as decision date looms; Sarepta welcomes...
Jeff Wade → The top leadership at Lexicon Pharmaceuticals is still undergoing a major makeover as president and COO Jeff Wade heads for the exit on Sept. 30 after 25 years with the Texas-based biotech....
View ArticleNovo axes Phase 2 of Forma-acquired drug in myelodysplastic syndromes
Novo Nordisk has ended one of the multiple trials testing the lead oral drug from its $1.1 billion Forma Therapeutics buyout, according to an update to the US federal trials database this week. The...
View ArticleClik here to view.
Novo says its CB1 drug helped shed weight, but efficacy and safety questions...
Novo Nordisk’s $1 billion bet last year on a small Canadian biotech could expand the Danish drug giant’s arsenal of obesity medicines, but it will first have to address safety concerns. On Friday, Novo...
View Article